ABT
Guidance: the market’s least favorite plot twist
Abbott spent earnings day doing that classic corporate move: putting a solid quarter on the board and then immediately lowering the bar for the next one. The company said Q2 2026 adjusted EPS should land between $1.25 and $1.31, which is a bit awkward when analysts were expecting $1.34.
The good news, buried under the fine print
The quarter itself wasn’t a disaster. Abbott reported $1.15 in EPS, which matched expectations, and revenue came in at $11.16 billion, ahead of the $10.99 billion consensus. So the business is still moving product. It’s just the forward-looking part that has investors squinting at the screen like, “Wait, that’s the plan?”
Dividend candy, but with a sour aftertaste
Abbott also declared a quarterly dividend of $0.63, or $2.52 annualized, which keeps the income crowd happy and gives the stock a little defensive glow. But dividend checks don’t always cancel out guidance cuts, especially when the company also set FY 2026 EPS guidance at $5.38 to $5.58 — a range investors will now dissect like they’re looking for hidden clues in a detective novel.
Why you should care
This is the kind of update that can keep a blue-chip healthcare name from feeling sleepy. The core business looks healthy enough, but softer forward guidance plus some analyst target cuts and insider selling can turn “steady compounder” into “show me the next quarter.”
Big picture: Abbott is still Abbott — big, diversified, and cash-generative — but on earnings day, the market mostly heard the guidance trim, not the beat.